Evidence map›Paper›PMID 39561884›Full record

ArticleGenomics2024

A fundamental and theoretical framework for mutation interactions and epistasis.

Christopher J Giacoletto, Ronald Benjamin, Jerome I Rotter, Martin R Schiller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Central Dogma Cycle and Network: A Model for Cell Memory.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher J GiacolettoNevada Institute of Personalized Medicine, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA; School of Life Sciences, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA; Heligenics Inc., 10530 Discovery Drive, Las Vegas, NV 89135, USA.
Ronald BenjaminNevada Institute of Personalized Medicine, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA; School of Life Sciences, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA.
Jerome I RotterHeligenics Inc., 10530 Discovery Drive, Las Vegas, NV 89135, USA; The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Martin R SchillerNevada Institute of Personalized Medicine, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA; School of Life Sciences, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA; Heligenics Inc., 10530 Discovery Drive, Las Vegas, NV 89135, USA. Electronic address: martin.schiller@unlv.edu.

Funding

The Genome Analysis and Sequencing Pipeline (GASP)P20GM121325 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI CHEN, JINGCHUN · 2018 to 2022
$11.5M
The C-terminomeR15GM107983 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI SCHILLER, MARTIN R · 2013 to 2013
$443k
A novel high-throughput functional screen based upon chimeric minimotif decoysR21AI116411 · NIAID · UNIVERSITY OF NEVADA LAS VEGAS · PI SCHILLER, MARTIN R · 2015 to 2016
$407k
High-throughput functional analysis and clinical relevance of all possible variants of a geneR43HG012537 · NHGRI · HELIGENICS INC · PI SCHILLER, MARTIN R. · 2023 to 2023
$399k
Identification of short functional motifs as potential drug targets for HIVR21AI078708 · NIAID · UNIVERSITY OF NEVADA LAS VEGAS · PI SCHILLER, MARTIN R · 2008 to 2009
$368k
HIV Toolbox, an interactive, visual, and customizable HIV Protein OntologyR56AI109156 · NIAID · UNIVERSITY OF NEVADA LAS VEGAS · PI SCHILLER, MARTIN R · 2014 to 2014
$332k
NHGRI NIH HHS R43 HG012537NIAID NIH HHS R21 AI078708NIAID NIH HHS R21 AI116411NIAID NIH HHS R56 AI109156NIGMS NIH HHS P20 GM121325NIGMS NIH HHS R15 GM107983
6 · The paper itself

Abstract

Many pathological conditions are a result of intragenic epistasis; however, there are ambiguities in current epistasis models. Herein, the new Mutation Interaction Spectrum model defines a discrete outcome, named a Mutation Interaction, for each double point mutation in a gene and its component single mutations. The model is a universal genetic model of all types of mutation interactions and their functional outcomes and is derived from digital logic, commonly used in electrical engineering. Mutation interactions are normally classified as positive and negative epistasis. The model logics unifies common genetic relationships into one model, normalizing biological nomenclature, and disambiguates them with the 16 possible logic-based interactions. The model was tested by assaying transcriptional activity induced by HIV-1 Tat protein, for a random sampling of 3429 double mutations and all 1615 single mutations. All possible types of logic were observed for the Tat mutation interactions.

Indexed as

Epistasis, GeneticModels, GeneticHIV-1HumansMutationPoint Mutationtat Gene Products, Human Immunodeficiency Virustat Gene Products, Human Immunodeficiency VirusDigital logicDrug resistanceEvolutionGeneticsHIVIntragenic epistasisMutantsPhylogenetic treesTat

Identifiers

PMID39561884
PMCPMC11752442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.